Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms

Clinical Chemistry

Volumn 57, Issue 7, 2011, Pages 995-1004

  Stephan, Carsten ^a,b   Siemßen, Kerstin ^a   Cammann, Henning ^a   Friedersdorff, Frank ^a   Deger, Serdar ^a   Schrader, Mark ^a   Miller, Kurt ^a   Lein, Michael ^a,b,c   Jung, Klaus ^a,b   Meyer, Hellmuth Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c University Teaching Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PARAMETER; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CALIBRATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 79959722977     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.151472     Document Type: Article

References (34)

1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78. (Pubitemid 351430866)
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
3. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007;52:89-97. (Pubitemid 46803013)
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
5. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007;249:30-9. (Pubitemid 46437279)
6. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007;43:1918-26. (Pubitemid 47287733)
7. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7. (Pubitemid 28233009)
8. Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 2007;249:18-29. (Pubitemid 46428002)
9. Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, et al. New markers and multivariate models for prostate cancer detection. Anticancer Res 2009;29:2589-600.
10. Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H, Graefen M. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007;99:794-800. (Pubitemid 46439569)
11. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005;173:1930-4. (Pubitemid 40675214)
12. Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999;45: 987-94. (Pubitemid 29340535)
13. Filella X, Alcover J, Quintó L, Molina R, Bosch-Capblanch X, Carretero P, Ballesta AM. Evaluation of a multivariate prostate-specific antigen and percentage of free prostate-specific antigen logistic regression model in the diagnosis of prostate cancer. Tumour Biol 1999;20:312-8.
14. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006;52:1568-74. (Pubitemid 44148320)
15. Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59-64. (Pubitemid 43032467)
16. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 2007;52:436-44.
17. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 2008;54:601-11.
18. Utsumi T, Kawamura K, Suzuki H, Kamiya N, Imamoto T, Miura J, et al. External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets. Int J Urol 2009;16:416-9.
19. Stephan C, Cammann H, Meyer HA, Müller C, Deger S, Lein M, Jung K. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int 2008;102:799-805.
20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233)
21. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.
22. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54:274-90.
23. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007;99:1427-31. (Pubitemid 47164809)
24. Stephan C, Kahrs AM, Klotzek S, Reiche J, Müller C, Lein M, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med 2008;46:623-9. (Pubitemid 351749111)
25. Stenman UH, Leinonen J, Zhang WM, Finne P, Wu P. The clinical importance of free prostate-specific antigen (PSA). Curr Opin Urol 1998;8:393-9. (Pubitemid 28479232)
26. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74. (Pubitemid 44728772)
27. Obuchowski NA, Lieber ML, Wians FH Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 2004;50:1118-25. (Pubitemid 38824221)
28. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35. (Pubitemid 46294733)
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. (Pubitemid 351193639)
30. Benecchi L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD. A novel nomogram to predict the probability of prostate cancer on repeat biopsy. J Urol 2008;180:146-9.
31. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int J Urol 2008;15:598-603. (Pubitemid 351989334)
32. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007;25:3582-8. (Pubitemid 47372595)
33. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, Stenman UH. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 2004;111:310-5. (Pubitemid 38924712)
34. Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol 2009;9:7.